NEW YORK– The Michael J. Fox Foundation (MJFF) has announced third-quarter 2012 participants in its Partnering Program. Selected from the most promising research projects in the MJFF portfolio, Partnering Program participants’ research projects are presented directly to industry groups who may wish to invest in further development of the project. By connecting industry leaders with those projects ripe for investment, the Foundation aims to drive forward promising projects in PD research through the pipeline of drug development, and eventually into patients’ hands.
Non-confidential overviews of select MJFF-funded projects are shared with industry contacts and more broadly via MJFF’s Web site on a quarterly basis.
MJFF-supported projects featured in Q3 include:
- Clinical work from PsychoGenics, in association with Lund University, studying eltoprazine as a treatment for levodopa-induced dyskinesias (LID) in PD.
- Completed pre-clinical work from Gliacor Therapeutics that tested the efficacy and mechanism of action of a novel series of phytochemical-based compounds with high anti-inflammatory activity in glial cells.
Overviews from awardees Biodesy, Neurodyn, the Virginia College of Osteopathic Medicine and Duke University, National Jewish Health and University of Colorado Denver in collaboration with Aeolus Pharmaceuticals were showcased in Q2 2012.
To date, the Foundation has funded over $300 million in research, over $79 million of which has been directed to more than 165 unique projects led by industry partners.
To view the Q3 2012 participants, and all MJFF awardees featured via the Partnering Program thus far, visit the Partnering Program page at https://www.michaeljfox.org/research/opportunities-for-industry/partnering-program.html.
To find out more, please contact the MJFF Research Partnerships team at ResearchPartnerships@michaeljfox.org.